HBIO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

23.10M

-5.93%

0.005

-125%

21.25M

-2.41%

0.035

-41.67%

22.75M

+11.25%

-0.005

-50%

Estimates Revision

The market is revising No Change the revenue expectations for Harvard Bioscience, Inc. (HBIO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 42.66%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+42.66%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast HBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HBIO is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

2.00

Averages

2.00

High

2.00

Current: 0.000

Low

2.00

Averages

2.00

High

2.00

Benchmark

Bruce Jackson

Speculative Buy

downgrade

$3 -> $2

2025-09-10

Reason

Benchmark

Bruce Jackson

Price Target

$3 -> $2

2025-09-10

downgrade

Speculative Buy

Reason

Benchmark analyst Bruce Jackson lowered the firm's price target on Harvard Bioscience to $2 from $3 and keeps a Speculative Buy rating on the shares. Concerns about basic research funding, drug pricing, and tariffs create an uncertain environment for the sector that seems likely to persist for the near future, says the analyst, who cites the heightened risk profile for the firm's lowered target.

Benchmark

Speculative Buy

downgrade

2025-05-13

Reason

Benchmark

Price Target

2025-05-13

downgrade

Speculative Buy

Reason

Benchmark lowered the firm's price target on Harvard Bioscience to $3 from $4.50 and keeps a Speculative Buy rating on the shares. The outlook for end-user markets in biomedical research continues to be challenging due to uncertainty around China tariffs, NIH funding, and biopharmaceutical research activity, which leads the firm to lower its 2025 revenue estimate as a result. However, despite the near-term uncertainty, management remains optimistic about the 2025 prospects for newly launched products, says the analyst, who believes shares could experience multiple expansion if the company continues to execute its plan to grow the business organically, increase cash flow, and pay down debt.

Keybanc

Paul Knight

Buy

Hold

Downgrades

n/a

2025-04-09

Reason

Keybanc

Paul Knight

Price Target

n/a

2025-04-09

Downgrades

Buy

Hold

Reason

KeyBanc downgraded Harvard Bioscience to Sector Weight from Overweight.

Benchmark

Bruce Jackson

Buy

Maintains

$5.5 → $4.5

2025-03-24

Reason

Benchmark

Bruce Jackson

Price Target

$5.5 → $4.5

2025-03-24

Maintains

Buy

Reason

Benchmark lowered the firm's price target on Harvard Bioscience to $4.50 from $5.50 and keeps a Speculative Buy rating on the shares. End-user markets in biomedical research continue to be challenging for Harvard, says the analyst, who is lowering estimates as a result.

Valuation Metrics

The current forward P/E ratio for Harvard Bioscience Inc (HBIO.O) is 7.67, compared to its 5-year average forward P/E of 23.54. For a more detailed relative valuation and DCF analysis to assess Harvard Bioscience Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

23.54

Current PE

7.67

Overvalued PE

42.75

Undervalued PE

4.34

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

14.03

Current EV/EBITDA

5.04

Overvalued EV/EBITDA

20.09

Undervalued EV/EBITDA

7.96

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.39

Current PS

0.32

Overvalued PS

2.13

Undervalued PS

0.66

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

HBIO News & Events

Events Timeline

No data

News

5.0

2025-11-18CNBC

Larry Summers Withdraws from Public Engagements Amid Email Controversy in Jeffrey Epstein Files

8.0

2025-10-13CNBC

Experts advise on ways to safeguard children as they increasingly rely on AI chatbots for critical thinking.

7.0

2025-09-03CNBC

Judge overturns Trump administration's $2.2 billion funding freeze for Harvard

People Also Watch

Frequently Asked Questions

What is Harvard Bioscience Inc (HBIO) stock price today?

The current price of HBIO is 0.6304 USD — it has decreased -3.37 % in the last trading day.

What is Harvard Bioscience Inc (HBIO)'s business?

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.

What is the price predicton of HBIO Stock?

What is Harvard Bioscience Inc (HBIO)'s revenue for the last quarter?

Harvard Bioscience Inc revenue for the last quarter amounts to 20.59M USD, decreased -6.27 % YoY.

What is Harvard Bioscience Inc (HBIO)'s earnings per share (EPS) for the last quarter?

Harvard Bioscience Inc. EPS for the last quarter amounts to -0.03 USD, decreased -72.73 % YoY.

What changes have occurred in the market's expectations for Harvard Bioscience Inc (HBIO)'s fundamentals?

How many employees does Harvard Bioscience Inc (HBIO). have?

Harvard Bioscience Inc (HBIO) has 330 emplpoyees as of January 10 2026.

What is Harvard Bioscience Inc (HBIO) market cap?

Today HBIO has the market capitalization of 28.10M USD.